利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

448 条记录 (耗时 0.02 秒)

    POSITRON EMISSION TOMOGRAPHY USING GALLIUM-68 CHELATES
    51.
    发明授权
    POSITRON EMISSION TOMOGRAPHY USING GALLIUM-68 CHELATES 有权
    与使用镓68螯合物的正电子发射断层摄影

    公开(公告)号：EP1075287B1

    公开(公告)日：2004-02-18

    申请号：EP99921656.7

    申请日：1999-05-06

    申请人： Immunomedics, Inc.

    发明人： GRIFFITHS, Gary, L. ,  MCBRIDE, William, J.

    IPC分类号： A61K51/08 ,  A61K47/48

    CPC分类号： B82Y5/00 ,  A61K47/6893 ,  A61K51/088

    摘要： A method of delivering Ga-68 to a target site is effected by administering a bi-specific antibody which specifically binds via a primary binding site to a substance produced by or associated with the target site and which specifically binds via a secondary binding site to a subsequently administered chelate-Ga-68 complex, and allowing the antibody to localize at the target site; optionally administering a clearing agent to clear non-localized bi-specific antibody rapidly from circulation; and administering a chelate-Ga-68 complex comprising Ga-68 chelated to Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH2 and allowing the chelate-Ga-68 complex to localize at the target site via specific binding by the secondary binding site of the bi-specific antibody. The targeted complex then can be used for PET imaging to give highly resolved images. Alternatively, the Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH2 can be conjugated to a targeting antibody fragment and used to elute Ga-68 from a generator, after which it is infused into a patient for direct targeting of the Ga-68 for PET imaging. Reagents and methods of making and using them also are provided.

    Method and kit for imaging organs and tissues, using labelled antibodies
    52.
    发明公开
    Method and kit for imaging organs and tissues, using labelled antibodies 失效
    一种用于器官和组织的成像方法和试剂盒，其中标记被使用的抗体

    公开(公告)号：EP1384488A2

    公开(公告)日：2004-01-28

    申请号：EP03076875.8

    申请日：1993-04-02

    申请人： Immunomedics, Inc.

    发明人： The designation of the inventor has not yet been filed

    IPC分类号： A61K51/10 ,  A61K49/00 ,  A61K49/16

    CPC分类号： G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

    摘要： The invention provides the use of an antibody or antibody fragment which specifically binds a marker produced by or associated with a cell or tissue in an organ of interest, said antibody or antibody fragment being labelled with a radioisotope or with a magnetic resonance image enhancing agent capable of external detection, in the manufacture of a medicament for use in a method of imaging hypoplastic, anatomically displaced or ectopic cells or tissues in a mammalian subject by scintigraphic or magnetic resonance imaging, wherein the amount of the labelled antibody or antibody fragment is sufficient to permit a scintigraphic image or an enhanced magnetic resonance image of said organ to be obtained. Also provided is a kit for use in such methods.

    摘要翻译： 本发明提供了使用特异性结合所产生或在感兴趣的器官的细胞或组织相关的标志物的抗体或抗体片段的抗体，所述抗体或抗体片段被用放射性同位素标记或与能够磁共振图像增强剂 外部检测的，在制备用于使用的药剂在成像发育不全的方法，在解剖学上在通过闪烁法或磁共振成像的哺乳动物受试者移位或异位细胞或组织，worin标记的抗体或抗体片段的量足以 允许闪烁照相图像或到所述器官的增强磁共振图像来获得。 所以，提供的是用于搜索方法使用的试剂盒。

    MULTIVALENT TARGET BINDING PROTEIN
    56.
    发明公开
    MULTIVALENT TARGET BINDING PROTEIN 有权
    多价靶结合蛋白

    公开(公告)号：EP1309705A2

    公开(公告)日：2003-05-14

    申请号：EP01962303.2

    申请日：2001-07-25

    申请人： Immunomedics Inc.

    发明人： LEUNG, Shui-on,Hong Kong Inst. Biotechnology Ltd

    IPC分类号： C12N15/62

    CPC分类号： C07K16/44 ,  A61K47/6803 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/06 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2319/00

    摘要： A novel multivalent target binding protein which comprises a first and a second polypeptides and has at least three target binding sites is described. The first polypeptide of the multivalent target binding protein comprises a first scFv molecule and a first immunoglobulin-like domain which preferably comprises an immunoglobulin light chain variable region domain. The second polypeptide of the multivalent target binding protein comprises a second scFv molecule and a second immunoglobulin-like domain which preferably comprises an immunoglobulin heavy chain variable region domain. The first scFv molecule and the first immunoglobulin-like domain are preferably linked via a first extra amino acid sequence which preferably comprises an immunoglobulin light chain constant region domain. The second scFv molecule and the second immunoglobulin-like domain are preferably linked via second extra amino acid sequence which preferably comprises an immunoglobulin heavy chain constant region domain. The first and second extra amino acid sequences preferably associate with each other via at least one disulfide bond. The multivalent target binding protein of the present invention is useful for treating and detecting tumors and infectious lesions.

    SITE-SPECIFIC LABELING OF DISULFIDE-CONTAINING TARGETING VECTORS
    60.
    发明公开
    SITE-SPECIFIC LABELING OF DISULFIDE-CONTAINING TARGETING VECTORS 有权
    位置指定盯人二硫键含导向载体

    公开(公告)号：EP1121153A1

    公开(公告)日：2001-08-08

    申请号：EP99951901.0

    申请日：1999-10-13

    申请人： Immunomedics, Inc.

    发明人： MCBRIDE, William, J. ,  GRIFFITHS, Gary, L.

    IPC分类号： A61K47/48

    CPC分类号： A61K51/1093 ,  A61K47/65 ,  A61K47/6809 ,  A61K47/6889 ,  A61K51/083 ,  A61K51/088 ,  A61K51/1027

    摘要： A method of producing a diagnostic or therapeutic conjugate of a protein, polypeptide or peptide containing at least one disulfide bond which is necessary to maintain its biological activity, and bearing at least one thiol-containing moiety linked thereto through a hydrazone or hydrazine linkage, is effected by contacting said protein, polypeptide or peptide with a thiol-reactive diagnostic or therapeutic agent, either preformed or generated in situ, to form a stable diagnostic or therapeutic conjugate of the protein, polypeptide or peptide without substantial cleavage of the disulfide bond. Diagnostic and therapeutic conjugates produced using the foregoing method, as well as kits for carrying out the method are provided.